Family

+

−

• No Family data available.

• 15 United States
• 10 France
• 8 Japan
• 7 China
• 5 Korea
• 2 Other

Patent Owner(s)

Patent Owner	Address
GONGWIN BIOPHARM CO LTD	3F NO 80 SEC 1 JIANGUO N RD ZHONGSHAN DIST TAIPEI 10449 TAIWAN

International Classification(s)

• A61K:PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOS....

• 2016 Application Filing Year
• A61K Class
• 19101 Applications Filed
• 13019 Patents Issued To-Date
• 68.16 % Issued To-Date

Inventor(s)

Inventor Name	Address	# of filed Patents	Total Citations
LI, LONGJIANG	Chengdu City, CN	5	2
# of filed Patents : 5 Total Citations : 2
Lin, Mao-Yuan	Taipei City, TW	15	20
# of filed Patents : 15 Total Citations : 20
Shih, Chia-Shun	Taipei City, TW	2	1
# of filed Patents : 2 Total Citations : 1
Wu, LESTER J	CAPE CORAL, US	3	5
# of filed Patents : 3 Total Citations : 5
ZHONG, NANSHAN	Guangzhou City, CN	16	7
# of filed Patents : 16 Total Citations : 7

Cited Art Landscape

Load Citation

• No Cited Art to Display

Loading Cited Art Landscape...

Patent Citation Ranking

• 1 Citation Count
• A61K Class

• 50.93 % this patent is cited more than
• 7 Age

Forward Cite Landscape

Load Citation

• No Forward Cites to Display

Loading Forward Cite Landscape...

Maintenance Fees

Fee	Large entity fee	small entity fee	micro entity fee	due date
7.5 Year Payment	$3600.00	$1800.00	$900.00	Sep 1, 2025
11.5 Year Payment	$7400.00	$3700.00	$1850.00	Sep 1, 2029

Fee	Large entity fee	small entity fee	micro entity fee
Surcharge - 7.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge - 11.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge after expiration - Late payment is unavoidable	$700.00	$350.00	$175.00
Surcharge after expiration - Late payment is unintentional	$1,640.00	$820.00	$410.00

Full Text

US Patent Application No: 2018/0055,796

PHARMACEUTICAL COMPOSITION EXHIBITING ANTI-TUMOR ACTIVITY, METHOD FOR TREATING PATIENT SUFFERING FROM CANCER AND METHOD FOR INHIBITING TUMOR GROWTH

---

Abstract

---

A pharmaceutical composition exhibiting anti-tumor activity is provided. The pharmaceutical composition comprises para-toluenesulfonamide (PTS) and a pharmaceutically acceptable carrier. The pharmaceutical composition is used for treating squamous-cell carcinoma. The present invention further provides a method for treating a patient suffering from cancer and a method for inhibiting tumor growth.

---

 

---

Description

---

Claims

---

Claims data not available

---

Legal Events

• No Legal Status data available.